Navigation Links
Sinovac Files Annual Report on Form 20-F
Date:4/30/2013

BEIJING, April 30, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccine products in China, announced today that it has filed its 2012 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2012 on April 30, 2013.  The Annual Report on Form 20-F is now available on the Company's website under SEC Filing in the Investor Relations section.

The Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge.  Requests for a hard copy of the 2012 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing details on the request form.

About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza and mumps, as well as animal rabies vaccine.  In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program.  The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program.  Sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot, and mouth disease), pneumococcal conjugate, pneumococcal polysaccharides, varicella and rubella.  Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac was also granted a license to commercialize seasonal flu vaccine in Mexico.

Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Contact:
Helen Yang / Chris Lee
Sinovac Biotech Ltd. 
Tel:  +86-10-8279-9659/ 9696
Fax:  +86-10-6296-6910 
Email: ir@sinovac.com

Investors 
Stephanie Carrington 
The Ruth Group 
Tel: +1-646-536-7017 
Email: scarrington@theruthgroup.com

Media 
Victoria Aguiar 
The Ruth Group 
Tel: +1-646-536-7013 
Email: vaguiar@theruthgroup.com 


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
2. Sinovac Reports Unaudited Third Quarter 2012 Financial Results
3. Sinovac to Host Conference Call to Report Third Quarter 2012 Unaudited Financial Results
4. Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
5. Sinovac Holds 2012 Annual General Meeting of Shareholders
6. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
7. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
8. Sinovac Schedules 2012 Annual Meeting of Shareholders
9. Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
10. Sinovac Reports Unaudited First Quarter 2012 Financial Results
11. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... ... ... Astellas is a pharmaceutical ...
Breaking Medicine Technology:
(Date:6/26/2016)... Viejo, California (PRWEB) , ... June 26, 2016 , ... ... Final Cut Pro X. , "Film editors can give their videos a whole new ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
Breaking Medicine News(10 mins):